Abdallah Abunamoos, Mohammad Moayad Ahmad Alghaniem, Fares A Qtaishat, Yumna Aljazi, Leen Omar Al-Omari, Izere Salomon, Bara M Hammadeh, Khaled Moghib
{"title":"与口服和替代方案相比，持续皮下注射ND0612治疗帕金森病运动波动的有效性和安全性：一项系统综述和荟萃分析","authors":"Abdallah Abunamoos, Mohammad Moayad Ahmad Alghaniem, Fares A Qtaishat, Yumna Aljazi, Leen Omar Al-Omari, Izere Salomon, Bara M Hammadeh, Khaled Moghib","doi":"10.1007/s10072-025-08257-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Continuous subcutaneous infusion of levodopa/carbidopa (ND0612) is a promising alternative to oral therapy for Parkinson's disease. Motor fluctuations and \"off time\" significantly impact the quality of life in advanced diseases. This meta-analysis evaluates the effectiveness of ND0612 in reducing \"off time,\" improving the overall quality of life, and enhancing sleep quality.</p><p><strong>Method: </strong>A comprehensive search of 549 studies was performed, and five eligible studies (n = 327) were included after intense screening. The ROB2 tool and ROBINS1 were used to assess the quality of the included studies. The outcomes assessed included reductions in \"off time\" (hours), quality of life (PDQ-39 scores), and sleep quality (PDSS scores). Statistical heterogeneity was assessed using the I<sup>2</sup> and tau<sup>2</sup> statistics.</p><p><strong>Results: </strong>The meta-analysis showed a significant reduction in OFF time for ND0612 compared to oral regimens, with a standardized mean difference (SMD) of -0.53 (95% CI: -0.76, -0.30), and compared to placebo with an SMD of -0.30 (95% CI: -1.05, 0.44). For improvement in quality of life, a favorable effect of ND0612 was shown compared to oral regimens (SMD = -0.31, 95% CI: -0.54, -0.08) and placebo (SMD = 0.44, 95% CI: 1.19, -0.32). Sleep quality (PDSS scores) demonstrated a slight improvement compared with oral regimens (SMD = -0.21, 95% CI: -0.44, 0.02) and a more significant improvement compared with placebo (SMD = -0.42, 95% CI: -0.87, 0.03). Overall, ND0612 provided consistent benefits in reducing OFF time and enhancing both quality of life and sleep in patients with Parkinson's disease.</p><p><strong>Conclusion: </strong>ND0612 significantly reduced \"off time\" and improved quality of life among Parkinson's disease patients experiencing motor fluctuations. However, its effect on sleep quality was inconsistent, with no clear, robust benefit demonstrated. Overall, this analysis supports ND0612 as an effective therapeutic option in patients with advanced Parkinson's disease.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of continuous subcutaneous ND0612 Infusion compared to oral and alternative regimens in managing motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.\",\"authors\":\"Abdallah Abunamoos, Mohammad Moayad Ahmad Alghaniem, Fares A Qtaishat, Yumna Aljazi, Leen Omar Al-Omari, Izere Salomon, Bara M Hammadeh, Khaled Moghib\",\"doi\":\"10.1007/s10072-025-08257-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Continuous subcutaneous infusion of levodopa/carbidopa (ND0612) is a promising alternative to oral therapy for Parkinson's disease. Motor fluctuations and \\\"off time\\\" significantly impact the quality of life in advanced diseases. This meta-analysis evaluates the effectiveness of ND0612 in reducing \\\"off time,\\\" improving the overall quality of life, and enhancing sleep quality.</p><p><strong>Method: </strong>A comprehensive search of 549 studies was performed, and five eligible studies (n = 327) were included after intense screening. The ROB2 tool and ROBINS1 were used to assess the quality of the included studies. The outcomes assessed included reductions in \\\"off time\\\" (hours), quality of life (PDQ-39 scores), and sleep quality (PDSS scores). Statistical heterogeneity was assessed using the I<sup>2</sup> and tau<sup>2</sup> statistics.</p><p><strong>Results: </strong>The meta-analysis showed a significant reduction in OFF time for ND0612 compared to oral regimens, with a standardized mean difference (SMD) of -0.53 (95% CI: -0.76, -0.30), and compared to placebo with an SMD of -0.30 (95% CI: -1.05, 0.44). For improvement in quality of life, a favorable effect of ND0612 was shown compared to oral regimens (SMD = -0.31, 95% CI: -0.54, -0.08) and placebo (SMD = 0.44, 95% CI: 1.19, -0.32). Sleep quality (PDSS scores) demonstrated a slight improvement compared with oral regimens (SMD = -0.21, 95% CI: -0.44, 0.02) and a more significant improvement compared with placebo (SMD = -0.42, 95% CI: -0.87, 0.03). Overall, ND0612 provided consistent benefits in reducing OFF time and enhancing both quality of life and sleep in patients with Parkinson's disease.</p><p><strong>Conclusion: </strong>ND0612 significantly reduced \\\"off time\\\" and improved quality of life among Parkinson's disease patients experiencing motor fluctuations. However, its effect on sleep quality was inconsistent, with no clear, robust benefit demonstrated. Overall, this analysis supports ND0612 as an effective therapeutic option in patients with advanced Parkinson's disease.</p>\",\"PeriodicalId\":19191,\"journal\":{\"name\":\"Neurological Sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10072-025-08257-w\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10072-025-08257-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Efficacy and safety of continuous subcutaneous ND0612 Infusion compared to oral and alternative regimens in managing motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
Background: Continuous subcutaneous infusion of levodopa/carbidopa (ND0612) is a promising alternative to oral therapy for Parkinson's disease. Motor fluctuations and "off time" significantly impact the quality of life in advanced diseases. This meta-analysis evaluates the effectiveness of ND0612 in reducing "off time," improving the overall quality of life, and enhancing sleep quality.
Method: A comprehensive search of 549 studies was performed, and five eligible studies (n = 327) were included after intense screening. The ROB2 tool and ROBINS1 were used to assess the quality of the included studies. The outcomes assessed included reductions in "off time" (hours), quality of life (PDQ-39 scores), and sleep quality (PDSS scores). Statistical heterogeneity was assessed using the I2 and tau2 statistics.
Results: The meta-analysis showed a significant reduction in OFF time for ND0612 compared to oral regimens, with a standardized mean difference (SMD) of -0.53 (95% CI: -0.76, -0.30), and compared to placebo with an SMD of -0.30 (95% CI: -1.05, 0.44). For improvement in quality of life, a favorable effect of ND0612 was shown compared to oral regimens (SMD = -0.31, 95% CI: -0.54, -0.08) and placebo (SMD = 0.44, 95% CI: 1.19, -0.32). Sleep quality (PDSS scores) demonstrated a slight improvement compared with oral regimens (SMD = -0.21, 95% CI: -0.44, 0.02) and a more significant improvement compared with placebo (SMD = -0.42, 95% CI: -0.87, 0.03). Overall, ND0612 provided consistent benefits in reducing OFF time and enhancing both quality of life and sleep in patients with Parkinson's disease.
Conclusion: ND0612 significantly reduced "off time" and improved quality of life among Parkinson's disease patients experiencing motor fluctuations. However, its effect on sleep quality was inconsistent, with no clear, robust benefit demonstrated. Overall, this analysis supports ND0612 as an effective therapeutic option in patients with advanced Parkinson's disease.
期刊介绍：
Neurological Sciences is intended to provide a medium for the communication of results and ideas in the field of neuroscience. The journal welcomes contributions in both the basic and clinical aspects of the neurosciences. The official language of the journal is English. Reports are published in the form of original articles, short communications, editorials, reviews and letters to the editor. Original articles present the results of experimental or clinical studies in the neurosciences, while short communications are succinct reports permitting the rapid publication of novel results. Original contributions may be submitted for the special sections History of Neurology, Health Care and Neurological Digressions - a forum for cultural topics related to the neurosciences. The journal also publishes correspondence book reviews, meeting reports and announcements.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
